Cargando…

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been approved as second‐line therapy for advanced non–small cell lung cancers (NSCLCs) progressing after platinum‐based chemotherapy. However, some patients' disease progressed rapidly and sometimes exhibited explosive tumor progression. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vergnenegre, Alain, Geier, Margaux, Guisier, Florian, Lamy, Regine, Comet, Bénédicte, Le Garff, Gwenaelle, Do, Pascal, Janicot, Henri, Morel, Hugues, Decroisette, Chantal, Andre, Michel, Falchero, Lionel, Paleiron, Nicolas, Monnet, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970062/ https://www.ncbi.nlm.nih.gov/pubmed/31747137 http://dx.doi.org/10.1002/cam4.2716

Ejemplares similares

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
por: Vergnenègre, Alain, et al.
Publicado: (2019)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
por: Arpin, Dominique, et al.
Publicado: (2020)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015)

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report
por: Domblides, Maël, et al.
Publicado: (2021)

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)
por: LeCaer, H, et al.
Publicado: (2011)

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
por: Christos, Chouaid, et al.
Publicado: (2012)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
por: Auliac, Jean-Bernard, et al.
Publicado: (2019)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
por: Lesueur, Paul, et al.
Publicado: (2018)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

Effect on eNOS/NO Pathway in MIRI rats with preconditioning of GFPC from Dang Gui Si Ni decoction
por: Qian, Guo-qiang, et al.
Publicado: (2014)

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung
por: Agar, Camille, et al.
Publicado: (2020)

509P COVID-19 disease among lung cancer (LC) patients: Data from a real-life prospective multicentric study
por: Molinier, O., et al.
Publicado: (2022)

FDG PET and CT radiomics in diagnosis and prognosis of non-small-cell lung cancer
por: Hannequin, Pascal, et al.
Publicado: (2022)

EXM-86-04: 17/04/1986
por: Malandain, E.
Publicado: (1986)

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
por: Corre, Romain, et al.
Publicado: (2018)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies
por: Debieuvre, Didier, et al.
Publicado: (2022)

CHEP'04
Publicado: (2004)

CHEP'04
Publicado: (2004)

CHEP'04
Publicado: (2004)

CHEP'04
Publicado: (2004)

Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
por: Pirlog, Radu, et al.
Publicado: (2022)

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
por: Amrane, Karim, et al.
Publicado: (2020)

CCM 84-04
Publicado: (1984)

CCM no. 81/04
Publicado: (1981)

PSB93#04
Publicado: (1993)

EXM 93-04
por: Daems, G, et al.
Publicado: (1993)

EXM 90-04
por: Daems, G
Publicado: (1990)

EXM 91-04
por: Daems, G, et al.
Publicado: (1991)

LIN92#04
Publicado: (1992)

EXM 92-04
por: Daems, G
Publicado: (1992)

EXM 82-04
Publicado: (1982)

PMM 85-04
Publicado: (1985)

CCM 88.04
por: Raich, U
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_76ij590j434ufg8v72m8dm9qq7